Several studies support the suppression of LIFR signalling as potential target in inhibiting cell growth and tumour progression (9), and we have shown recently, that LIFR-mediated antagonism supports the anti-oncogenic effect of mifepristone in pancreatic cancer and chemoresistance (20). Here, LIFR is linked to pancreatic neoplasm.